Literature DB >> 19355912

Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines.

Stergios A Polyzos1, Jannis Kountouras, Christos Zavos.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of common hepatic disorders in western countries, with multiple consequences and its incidence is paralleling the increasing numbers of overweight and obese individuals worldwide. The pathogenesis of NAFLD is thought to be related mainly with insulin resistance (IR) syndrome and oxidative stress; the latter resulting from mitochondrial fatty acids (FFAs) oxidation, nuclear factor-kappaB (NFkappaB)-dependent inflammatory cytokine expression and adipocytokines may promote hepatocellular damage, inflammation, fibrosis and progressive liver disease. Adipocytokines and other recognized cytokines produced partially by inflammatory cells infiltrating adipose tissue, play an important role in the pathogenesis of IR and NAFLD, through complex and interactive paracrine and endocrine mechanisms. Some adipocytokines, including adiponectin and leptin decrease IR, while others, including tumor necrosis factor (TNF)-alpha, interleukin (IL)-6 and resistin enhance IR. The multi-hit hypothesis provides a model that summarizes the complex factors and interactions leading from adipocytokines, FFAs metabolism and IR to NAFLD. This review outlines the pathways involved in adipocytokines, IR and NAFLD sequence; the first part describes the impaired IR pathway leading to NAFLD and the second part the mechanisms by which adipocytokines influence IR and NAFLD development and progression. Understanding these complex mechanisms has evoked new therapeutic approaches, which may provide promising results to date.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19355912     DOI: 10.2174/156652409787847191

Source DB:  PubMed          Journal:  Curr Mol Med        ISSN: 1566-5240            Impact factor:   2.222


  79 in total

1.  Conjugated bile acid-activated S1P receptor 2 is a key regulator of sphingosine kinase 2 and hepatic gene expression.

Authors:  Masayuki Nagahashi; Kazuaki Takabe; Runping Liu; Kesong Peng; Xiang Wang; Yun Wang; Nitai C Hait; Xuan Wang; Jeremy C Allegood; Akimitsu Yamada; Tomoyoshi Aoyagi; Jie Liang; William M Pandak; Sarah Spiegel; Phillip B Hylemon; Huiping Zhou
Journal:  Hepatology       Date:  2015-03-09       Impact factor: 17.425

2.  Periostin on the road to nonalcoholic fatty liver disease.

Authors:  Stergios A Polyzos; Athanasios D Anastasilakis
Journal:  Endocrine       Date:  2015-11-19       Impact factor: 3.633

3.  The multi-hit process and the antagonistic roles of tumor necrosis factor-alpha and adiponectin in non alcoholic fatty liver disease.

Authors:  S A Polyzos; J Kountouras; Ch Zavos
Journal:  Hippokratia       Date:  2009-04       Impact factor: 0.471

4.  Multidetector-row computed tomography findings of sclerosing mesenteritis with associated diseases and its prevalence.

Authors:  Murat Canyigit; Ali Koksal; Ayca Akgoz; Taylan Kara; Murat Sarisahin; Okan Akhan
Journal:  Jpn J Radiol       Date:  2011-09-01       Impact factor: 2.374

Review 5.  What is the role of adiponectin in obesity related non-alcoholic fatty liver disease?

Authors:  Carmine Finelli; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2013-02-14       Impact factor: 5.742

6.  Association between circulating irisin and homocysteine in patients with nonalcoholic fatty liver disease.

Authors:  Stergios A Polyzos; Jannis Kountouras; Athanasios D Anastasilakis; Anastasia Margouta; Christos S Mantzoros
Journal:  Endocrine       Date:  2014-11-09       Impact factor: 3.633

7.  Circulating periostin in patients with nonalcoholic fatty liver disease.

Authors:  Stergios A Polyzos; Jannis Kountouras; Athanasios D Anastasilakis; Athanasios Papatheodorou; Panagiotis Kokkoris; Evangelos Terpos
Journal:  Endocrine       Date:  2016-10-13       Impact factor: 3.633

8.  Insulin resistance and chronic liver disease.

Authors:  Takumi Kawaguchi; Eitaro Taniguchi; Minoru Itou; Masahiro Sakata; Shuji Sumie; Michio Sata
Journal:  World J Hepatol       Date:  2011-05-27

Review 9.  Irisin in metabolic diseases.

Authors:  Stergios A Polyzos; Athanasios D Anastasilakis; Zoe A Efstathiadou; Polyzois Makras; Nikolaos Perakakis; Jannis Kountouras; Christos S Mantzoros
Journal:  Endocrine       Date:  2017-11-23       Impact factor: 3.633

10.  Activin A and follistatin in patients with nonalcoholic fatty liver disease.

Authors:  Stergios A Polyzos; Jannis Kountouras; Athanasios D Anastasilakis; Georgios Α Triantafyllou; Christos S Mantzoros
Journal:  Metabolism       Date:  2016-07-25       Impact factor: 8.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.